30 closest matches · ranked by relevance
Myelodysplastic Syndrome
Primary: One Year Overall Survival of Allogeneic Transplant Recipients After Transplantation — 50 percentage of participants
Myelodysplastic Syndromes · Thrombocytopenia
Primary: Number of Participants With Response Between Weeks 16 and 20 — 11 Participants
Leukemia, Myeloid, Acute · Myelodysplastic Syndromes
Primary: Phase I: Maximum Tolerated Dose (MTD) of LBH589 When Given in Combination With Decitabine — 40 mg (level 5b dosing schedule)
Myelodysplastic Syndrome
Primary: Number of Participants With Response — 2; 2; 4; 6 participants
Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants With a Response (Complete Remissions (CR), Complete Remissions With Incomplete Platelet Recovery [CRp] and Partial Responses) — 1; 1; 0 participants
High Risk Myelodysplastic Syndrome
Primary: Number of Participants With a Complete Response (CR) — 25 Participants
Myelodysplastic Syndrome
Primary: Dosage Determination for IV-infusion of Vosaroxin in Int-2 or High-risk Mds — 200 mg/m^2
Leukemia
Primary: Number of Dose Limiting Toxicities for Determining Maximum Tolerated Dose (MTD) of Lenalidomide in Combination With 5-azacytidine (5-AZA) — 0; 0; 0; 0 participants
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities · Adult Acute Myeloid Leukemia With Del(5q) · Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Primary: Number of Participants With Response — 1; 4; 5; 3 Participants
Myelodysplastic Syndromes
Primary: Number of Participants With Confirmed Responses (Complete Remission, Partial Remission, or Hematologic Improvement) as Defined by the International Working Group…
Leukemia · Myeloproliferative Diseases
Primary: Number of Participants With Complete Response (CR) — 19 Participants
MDS
Primary: Percentage of Participants With at Least One Red Blood Cell (RBC) Transfusion During the Double-blind Treatment Period — 59.2; 36.1 percentage of participants — p=0.008
Myelodysplastic Syndrome
Primary: Percentage of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for ≥ 56 Days — 30.8; 11.9 Percentage of Participants — p=0.0005
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome · Acute Myeloid Leukemia/Transient Myeloproliferative Disorder · Adult Acute Myeloid Leukemia in Remission
Primary: Overall Survival — 6; 6 participants
Myelodysplastic Syndrome
Primary: The Number of Patients Who Achieved a Clinical Response — 5 Participants
Myelodysplastic Syndrome
Primary: Event Free Survival (EFS) at 1 Year — 26; 65 percentage of participants
Leukemia
Primary: Percentage of Participants With Relapse-free Survival (RFS) — 52 percentage of participants
Chronic Myelomonocytic Leukemia · de Novo Myelodysplastic Syndrome · Myelodysplastic Syndrome
Primary: Failure-free Survival (Failure Defined as Death or Relapse) — 6; 10 Participants
Myelodysplastic Syndromes
Primary: Kaplan-Meier Estimates for Median Time to Death From Any Cause — 24.46; 15.02 months — p=0.0001
Acute Myeloid Leukemia · Adult Acute Megakaryoblastic Leukemia · Adult Acute Monoblastic Leukemia
Primary: Progression-free Survival — 41.2; 26.9 percentage of patients
Leukemia · Myelodysplastic Syndromes
Primary: PHASE I: Maximum Tolerated Dose of Azacitidine — 75 mg/m2 subcutaneously for 5 days
Myelodysplastic Syndromes (MDS)
Primary: Overall Survival — 55; 58 Participants
Myelodysplastic Syndromes
Primary: Response to Treatment - Hematologic Improvement or Complete Response — 21 Participants
Leukemia · Myelodysplastic Syndromes · Myelodysplastic/Myeloproliferative Neoplasms
Primary: Complete Response Rate — 35.3 percentage of participants
Myelodysplastic Syndromes
Primary: Participants Who Achieved Red Blood Cell (RBC) -Transfusion Independence — 59 participants
Acute Myeloid Leukemia · Myeloid and Monocytic Leukemia · Myelodysplastic Syndromes
Primary: Efficacy of Combined Modality Treatment (Ruxolitinib, Decitabine, and DLI) for Relapsed AML or MDS Post Allo-HCT: Rate of Overall Survival (OS) — 36 Percentage of…
Acute Myeloid Leukemia · Higher Risk Myelodysplastic Syndrome
Primary: Stage 1: Dosing Schedule of Low-dose Cyclophosphamide — 6; 6 Participants
Myelodysplastic Syndromes
Primary: Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for >= 26 Weeks (182 Days) — 3; 20; 23 Participants — p=<0.001
Acute Myelogenous Leukemia · Myelodysplastic Syndrome · Leukemia
Primary: Number of Participants With Complete Remission — 0; 0; 0; 2 participants
Leukemia
Primary: Overall Survival (OS) — 7.5 Months